Currently, there are 1.47B common shares owned by the public and among those 1.47B shares have been available to trade.
The company’s stock has a 5-day price change of 3.72% and 12.04% over the past three months. BSX shares are trading 51.44% year to date (YTD), with the 12-month market performance up to 80.00% higher. It has a 12-month low price of $48.35 and touched a high of $87.28 over the same period. BSX has an average intraday trading volume of 5.57 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.69%, 7.65%, and 20.36% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Boston Scientific Corp. (NYSE: BSX) shares accounts for 91.74% of the company’s 1.47B shares outstanding.
It has a market capitalization of $128.93B and a beta (3y monthly) value of 0.80. The stock’s trailing 12-month PE ratio is 70.83, while the earnings-per-share (ttm) stands at $1.24. The company has a PEG of 5.45 and a Quick Ratio of 1.14 with the debt-to-equity ratio at 0.54. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.66% over the week and 1.49% over the month.
Earnings per share for the fiscal year are expected to increase by 17.49%, and 13.54% over the next financial year. EPS should grow at an annualized rate of 13.00% over the next five years, compared to -2.05% over the past 5-year period.
Looking at the support for the BSX, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on May 30, 2024, with the firm’s price target at $90. Mizuho coverage for the Boston Scientific Corp. (BSX) stock in a research note released on February 01, 2024 offered a Buy rating with a price target of $80. Robert W. Baird was of a view on July 19, 2023 that the stock is Outperform, while CL King gave the stock Buy rating on June 30, 2023, issuing a price target of $64. Morgan Stanley on their part issued Overweight rating on May 30, 2023.
